These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28508149)

  • 21. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a
    Naidoo D; de Lencastre A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death.
    Yoon JH; Mo JS; Kim MY; Ann EJ; Ahn JS; Jo EH; Lee HJ; Lee YC; Seol W; Yarmoluk SM; Gasser T; Kahle PJ; Liu GH; Belmonte JCI; Park HS
    Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2356-2368. PubMed ID: 28888991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-599 regulates the development of Parkinson's disease through mediating LRRK2 expression.
    Wu Q; Xi DZ; Wang YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):724-731. PubMed ID: 30720180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypothesis: Do miRNAs Targeting the Leucine-Rich Repeat Kinase 2 Gene (LRRK2) Influence Parkinson's Disease Susceptibility?
    Yılmaz ŞG; Geyik S; Neyal AM; Soko ND; Bozkurt H; Dandara C
    OMICS; 2016 Apr; 20(4):224-8. PubMed ID: 27093107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA XIST sponges miR-199a-3p to modulate the Sp1/LRRK2 signal pathway to accelerate Parkinson's disease progression.
    Zhou Q; Zhang MM; Liu M; Tan ZG; Qin QL; Jiang YG
    Aging (Albany NY); 2021 Jan; 13(3):4115-4137. PubMed ID: 33494069
    [No Abstract]   [Full Text] [Related]  

  • 27. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
    Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
    J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
    Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
    Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of LRRK2 in the regulation of dopamine receptor trafficking.
    Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C
    PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.
    Nucifora FC; Nucifora LG; Ng CH; Arbez N; Guo Y; Roby E; Shani V; Engelender S; Wei D; Wang XF; Li T; Moore DJ; Pletnikova O; Troncoso JC; Sawa A; Dawson TM; Smith W; Lim KL; Ross CA
    Nat Commun; 2016 Jun; 7():11792. PubMed ID: 27273569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner.
    Iannotta L; Fasiczka R; Favetta G; Zhao Y; Giusto E; Dall'Ara E; Wei J; Ho FY; Ciriani C; Cogo S; Tessari I; Iaccarino C; Liberelle M; Bubacco L; Taymans JM; Manzoni C; Kortholt A; Civiero L; Hilfiker S; Lu ML; Greggio E
    Cell Death Dis; 2024 Oct; 15(10):752. PubMed ID: 39419978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
    Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
    PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types.
    Bailey HM; Cookson MR
    J Parkinsons Dis; 2024; 14(7):1331-1352. PubMed ID: 38905056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.